A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2018
At a glance
- Drugs AK 002 (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions
- Sponsors Allakos
- 06 Jun 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
- 06 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Dec 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.